Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Yosra Aljawai, Denai Milton, Rohtesh Mehta, David Marin, Yago Nieto, George Chen, Betul Oran, Portia Smallbone, Chitra Hosing, Oren Pasvolsky, Amin Alousi, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 168.

https://doi.org/10.1182/blood-2025-168

Published: 2025

Journal Articles

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Blood (2025) 146 (Supplement 1): 6058.

https://doi.org/10.1182/blood-2025-6058

Published: 2025

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Blood (2025) 146 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2025-5951

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

Blood (2025) 146 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2025-1678

Published: 2025

Journal Articles

IL-39/IL-39R signaling drives acute graft-versus-host disease

Denggang Fu, Michael Martens, Michael Hendrix, Allison Pugel, Qiao Cheng, Amin Alousi, Iskra Pusic, George Carrum, Asad Bashey, Stephanie Lee, John Levine, Yongxia Wu, Mehdi Hamadani, Xue-Zhong Yu

Blood (2025) 146 (Supplement 1): 5865.

https://doi.org/10.1182/blood-2025-5865

Published: 2025

Journal Articles

Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations

Felipe Soto, Gordon Smilnak, Adarsh Suresh, Caroline Sublett, Guang-Shing Cheng, Jeffrey Sturek, Gabriela Rondon, Amin Alousi, Hemang Yadav, Ajay Sheshadri

Blood (2025) 146 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2025-4306

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Blood (2025) 146 (Supplement 1): 378.

https://doi.org/10.1182/blood-2025-378

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Roberta S. Azevedo, Hagop Kantarjian, Jayastu Senapati, Ian Bouligny, Alexandre Bazinet, Wei-Ying Jen, Amin Alousi, Uday Popat, Elizabeth Shpall, Naveen Pemmaraju, Nitin Jain, Eitan Kugler, Cody Belgarde, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2025-1630

Published: 2025

Journal Articles

Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax

Niranjan Khaire, Ian Bouligny, Ghayas Issa, Naval Daver, Courtney DiNardo, Elias Jabbour, Nicholas Short, Wei-Ying Jen, Guilin Tang, Sanam Loghavi, Melissa MacFarland, Amin Alousi, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3459.

https://doi.org/10.1182/blood-2025-3459

Published: 2025

Journal Articles

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Blood (2025) 146 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2025-1869

Published: 2025

Journal Articles

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Yesid Alvarado-Valero, Lucia Masarova, Mark Brandt, Debra Bull-Linderman, Naval Daver, Guillermo Montalban-Bravo, Alex Bataller, Guillermo Garcia-Manero, Ghayas C. Issa, Amin Alousi, Nicholas J. Short, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2023-182969

Published: 2023

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

IL-39/IL-39R signaling drives acute graft-versus-host disease

Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Optimizing essential, complex hematologic care for patients living with disabilities

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only